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Introduction
Extracorporeal renal replacement therapy (RRT) has 
been used for the supportive treatment of acute kidney 
injury (AKI) for over 60 years. Whereas treatment 
method  ologies have become increasingly sophisticated, 
the basic principles guiding the use of RRT have changed 
little. Th   ey aim at averting the immediately life-threaten-
ing consequences of severe renal dysfunction (acidosis, 
electrolyte imbalances, uremia, and ﬂ  uid  overload), 
preserving life, and allowing time for organ recovery to 
occur. Following these principles, one could argue that, 
as long as a minimum level of RRT is provided, the 
quality, quantity, and timing of RRT should not greatly 
aﬀ  ect outcome. However, considerable evidence that the 
develop  ment of AKI is independently associated with 
mortality now exists [1], suggesting that optimization of 
RRT could beneﬁ   t survival. Until now, however, little 
evidence or consensus regarding the optimum delivery of 
RRT has existed, resulting in wide variations in clinical 
practice [2]. Furthermore, irrespective of intensity, the 
superiority of continuous renal replacement therapy 
(CRRT) over intermittent hemodialysis (IHD) for RRT in 
the intensive care unit (ICU) remains controversial, 
although there is increasing international consensus that 
initial therapy with CRRT is preferable in hemo-
dynamically unstable patients [3-6]. Given that most 
patients critically ill with AKI do have hemodynamic 
instability, CRRT has become, worldwide, the dominant 
form of RRT for AKI in the ICU [2]. Furthermore, since a 
large majority of RRT treatments for AKI are now given 
in the ICU [7], CRRT is likely to be the most common 
modality for the initial treatment of AKI by RRT in the 
developed world.
As a continuous therapy, CRRT has the beneﬁ  t  of 
better mimicking normal renal function, while quantity 
of therapy delivered is more easily assessed and compared 
with endogenous renal function. Consequently, there has 
been continued interest in establishing the appropriate 
dose or intensity of this therapy. Two major multi-center 
randomized controlled trials (MC-RCTs) examining this 
question have now been performed: the Veterans Aﬀ  airs/
National Institutes of Health Acute Renal Failure Trial 
Network (ATN) study [4] and the Randomized Evaluation 
of Normal versus Augmented Level (RENAL) Replace-
ment Th  erapy Study [8]. Together, these trials provide, 
for the ﬁ   rst time, high-quality evidence to guide the 
prescription of CRRT in the ICU. Th   is review examines 
the results from these and earlier studies to summarize 
our current understanding of the most appropriate dose 
of CRRT to deliver during AKI in critical illness.
Assessing dose of continuous renal replacement 
therapy
To compare diﬀ  ering intensities of RRT, some measure of 
quantity of blood cleansing is needed. Quantity or dose of 
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clearance of urea (that is, the rate of plasma cleansing 
required to account for the rate of urea removal if the 
treatment separated all urea from the plasma processed). 
Such measurements are comparable to endogenous renal 
function assessed as glomerular ﬁ   ltration rate (GFR). 
Urea is chosen as an easily measured prototype for low-
molecular-weight products of metabolism. While tubular 
reabsorption prevents urea clearance from being an 
accurate measure of kidney GFR, such concerns do not 
apply to extracorporeal blood puriﬁ  cation.  Measuring 
total urea in the dialysis or ultraﬁ  ltration eﬄ   uent and 
con  tinuous plasma urea concentration could allow calcu-
lation of clearance. However, this is cumbersome and 
approxi  mations of dose are instead estimated from 
machine settings. Th   is process is very easy for continuous 
therapies. For a small uncharged molecule such as urea, 
clearance during continuous hemoﬁ   ltration (HF) is 
essentially equal to the ultraﬁ  ltration rate because the 
ﬁ  lter membrane negligibly impedes the passage of urea. 
Similarly, during continuous hemodialysis (HD), when 
the dialysis ﬂ  ow rate is much slower than the blood ﬂ  ow 
rate, urea concentration in the dialysate will equilibrate 
with that in the plasma and clearance can be approxi-
mated by the dialysate ﬂ  ow rate. Th   us, provided that no 
pre-dilution is applied, in any HF, HD, or hemodia-
ﬁ   ltration continuous therapy, the total clearance is 
approxi  mately the total ﬂ  ow of ﬂ  uid out of the dialyzer or 
ﬁ  lter (that is, the eﬄ   uent ﬂ  ow rate).
Th   e above approximations have been shown to 
correlate well with a more formal set of measurements of 
urea clearance [9]. Th   us, the dose of CRRT is reported as 
eﬄ   uent  ﬂ   ow in milliliter per hour or milliliter per 
kilogram of body weight per hour. Infusion of HF 
replace  ment solution as pre-dilution will reduce eﬀ  ective 
eﬄ   uent dose by the degree to which the plasma is diluted. 
Since this dilution eﬀ  ect is dependent on circuit blood 
ﬂ  ow, replacement ﬂ  uid rate, and hematocrit, these factors 
have to be measured to correctly assess dose when pre-
dilution is applied [9]. Most importantly, time spent oﬀ   
CRRT (circuit clotting, radiological investigations, and/
or surgical procedures) can be substantial and can impact 
azotemic control [10]. Th   e impact of these factors must 
be accounted for when prescribing therapy as it is the 
delivered and not the prescribed dose that will aﬀ  ect 
outcome. Finally, unlike urea, metabolites of higher 
molecular weight will interact signiﬁ  cantly with the dialy-
zer membrane. Similarly, other substances that signiﬁ  -
cantly bind to plasma proteins may be relatively retained 
in the plasma. In these cases, changes in eﬄ   uent ﬂ  ow rate 
may correlate poorly with changes in solute clearance. 
Th   us, it should be remembered that eﬄ   uent measures of 
dose, while reproducible and convenient, do not measure 
all aspects of blood cleansing in CRRT.
Clinical variation in continuous renal replacement 
therapy dose
Prescribed and delivered inten  sities of CRRT vary widely. 
Two multi-center observa  tional studies have documented 
CRRT dose in the ICU; in both studies, interquartile 
ranges for dose were large (15.3 to 27.7 mL/kg per hour 
in the BEST Kidney [Beginning and Ending Supportive 
Th   erapy for the Kidney] study [11] and 22.1 to 33.9 mL/
kg per hour in the DO-RE-MI [Dose Response 
Multicentre International collaborative initiative] study 
[12]). As units participating in these studies were 
recruited by expression of interest, one can assume far 
wider variation and lower delivered doses in units 
without an interest in research and the provision of 
CRRT. Much of this variation in dose may be accounted 
for by the use of standard doses of CRRT unadjusted for 
weight. For example, in the DO-RE-MI study, patients 
receiving the lowest CRRT doses were 33% heavier than 
those receiving the higher doses [13]. Th  is greatly 
confounds the interpretation of observational data on 
CRRT dose since weight is likely to have a complex causal 
relationship with outcome. Furthermore, even when 
used, weight estimation in the ICU can be highly error-
prone and it is far from clear whether estimates of ideal 
body weight, pre-morbid weight, ‘dry’ weight, or actual 
body weight should be used [13].
Dose-response relationship in continuous renal 
replacement therapy
Prior to the ATN and RENAL trials, four single-center 
studies had prospectively examined the relationship 
between CRRT dose and survival in critical illness 
(Table 1). All of these trials were, however, relatively small 
and varied in geographical location, patient case mix, and 
mode of CRRT. In the ﬁ  rst of these, Ronco and colleagues 
[14] randomly assigned 425 critically ill patients with AKI 
treated using continuous veno-venous hemoﬁ  ltration 
(CVVHF) at a single center to ultra  ﬁ  ltration rates of 20, 
35, or 45 mL/kg per hour. Survival 15 days after dis  con-
tinuation of CRRT was signiﬁ  cantly better in the highest- 
and intermediate-dose arms in comparison with the 
lowest-dose arm (58% and 57% versus 41%, respec  tively; 
P <0.001). Th   ree smaller randomized control trials subse-
quently examined RRT dose-response relationships in 
the ICU. Saudan and colleagues [15] randomly assigned 
206 patients with AKI in a single-center trial comparing 
CVVHF (mean ultraﬁ  ltration rate of 25 ± 5 mL/kg per 
hour) with continuous veno-venous hemodiaﬁ  ltration 
(CVVHDF) with the addition of a mean dialysate ﬂ  ow 
rate of 15 ± 5 mL/kg per hour to a similar mean ultra-
ﬁ  ltration rate (24 ± 6 mL/kg per hour): survival rates after 
90 days were 34% in the CVVHF group and 59% in the 
CVVHDF group (P = 0.0005), analyzed on an intention-
to-treat basis. While higher-intensity therapy involved a 
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clearances in continuous high-ﬂ  ux dialysis and CVVHF 
are quite similar [16], so this study is best regarded as 
investigating the eﬀ  ect of a dose increment.
On the other hand, two studies [17,18] that included 
200 and 106 patients, respectively, failed to demonstrate 
any beneﬁ  cial  eﬀ   ects of increased CRRT intensity on 
patient survival or renal recovery. Similarly, in the pros-
pective observational DO-RE-MI study [12], which inclu-
ded 338 patients undergoing CRRT for AKI in the ICU, 
higher-dose CRRT (deﬁ  ned as greater than 35 mL/kg per 
hour) was not associated with increased survival even 
after statistical adjustment for baseline characteristics 
(adjusted odds ratio for death 1.21, 95% conﬁ  dence 
interval 0.66 to 2.21; P = 0.537). Disparity in these results, 
concerns over the inherent biases of single-center studies 
[19], and consequent uncertainty about the optimum 
dosing of CRRT in the ICU led to the initiation of the 
ATN and RENAL studies.
Th   e ATN and RENAL studies were large, multi-center 
randomized controlled trials investigating the eﬀ  ects of 
RRT dose on survival and were conducted in ICUs 
through  out the US and in Australia and New Zealand, 
respectively (Table 2). Th  e ATN study [4] randomly 
assigned critically ill adults with AKI that required RRT 
to high-intensity or low-intensity RRT. High-intensity 
therapy consisted of pre-dilution CVVHDF to provide a 
total eﬄ   uent  ﬂ   ow rate of 35 mL/kg per hour or six 
sessions of IHD per week [4]. Low-intensity therapy 
consisted of CVVHDF to provide a total eﬄ   uent ﬂ  ow 
rate of 20 mL/kg per hour or thrice-weekly IHD. A very 
small number of patients received slow extended-dura-
tion dialysis six or three times weekly in the high-
intensity and low-intensity groups, respectively, in 
centers where CRRT was not available [4].  Within 
treatment groups, patients were allocated to CRRT or 
IHD when their cardiovascular Sequential Organ Failure 
Assessment (SOFA) score was 3 or 4 and received IHD if 
Table 1. Randomized controlled trials comparing dose of continuous renal replacement therapy in the intensive care unit
       Survival
Study Type  Number  Comparison  (measured  at)  Comment
RENAL [8] 2009  MC-RCT  1,508  40 mL/kg per hour versus  55% (day 90) 
      25 mL/kg per hour   55% NS 
     Post-dilution  CVVHDF   
ATN [4] 2008  MC-RCT  1,124  Pre-dilution CVVHDF 35 mL/kg per   46% (day 60)  Choice of CRRT/SLEDD versus IHD
      hour or 6/week SLEDD or 6/week     based on daily cardiovascular SOFA
     IHD  versus    score.
      Pre-dilution CVVHDF 20 mL/kg per   48% NS 
      hour or 3/week SLEDD or 3/week IHD 
Tolwani, et al. [17] 2008  SS-RCT  200  17 mL/kg per hour  49% (ICU or 30 days) 
      29 mL/kg per hour  56% NS 
      Pre-dilution CVVHDF (delivered doses)   
Saudan, et al. [15] 2006  SS-RCT  206  CVVHF: 1-2.5 L/hour versus  34% (day 90) 
      CVVHDF: 1-2.5 L/hour HF +   59% P = 0.0005 
      1-1.5 L/hour HD 
Bouman, et al. [18] 2002  2C-RCT  106  72-96 L/day early versus  74% (day 28)  Combined trial of dose and timing 
          early versus late.
      24-36 L/day early versus  69% NS 
      24-36 L/day late   75% NS 
     CVVHF   
Ronco, et al. [14] 2000  SS-RCT  425  20 mL/kg per hour versus  59% (day 15)  Unorthodox mortality outcome (day 
          15 after CRRT).
      35 mL/kg per hour versus  43% 
      45 mL/kg per hour  42% 
      Post-dilution CVVHF  20 versus 35 or 45 
       P <0.002 
        35 versus 45 NS 
2C-RCT, two-center randomized controlled trial; ATN, Veterans Aff  airs/National Institutes of Health Acute Renal Failure Trial Network; CRRT, continuous renal 
replacement therapy; CVVHDF, continuous veno-venous hemodiafi  ltration; CVVHF, continuous veno-venous hemofi  ltration; HD, hemodialysis; HF, hemofi  ltration; ICU, 
intensive care unit; IHD, intermittent hemodialysis; MC-RCT, multi-center randomized controlled trial; NS, not signifi  cant; RENAL, Randomized Evaluation of Normal 
versus Augmented Level; SOFA, Sequential Organ Failure Assessment; SLEDD, slow extended-duration daily dialysis; SS-RCT, single-center randomized controlled trial.
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However, patients receiving only CRRT switched to IHD 
if their cardiovascular SOFA score was 0 or 1 for more 
than 24 hours. CRRT was provided to 69.7% of patients 
as their initial therapy [20]. Switching between modalities 
occurred at similar rates in high-intensity and low-
intensity groups [20]. Among patients who survived to 
day 60, 84.2% received IHD at some stage during their 
ICU stay [20]. Given the controversies in dose compari-
son between treatment modalities and the use of IHD in 
many patients, the ATN trial might best be described as a 
test of maximization of intensity of RRT within current 
US practice rather than a direct test of a dose-response 
relationship for CRRT.
Table 2. Comparison of patient populations in VA/NIH ATN and RENAL studies
    VA/NIH ATN study  RENAL study
Number 1,124  1,508
Age, years   59.7  64.5
Percentage of males  70.6%  64.6%
CKD classifi  cationa  
 0-2  61.0%  68.6%
 3a  21.1%  9.7%
 3b  11.0%  10.4%
 4  Excluded  11.3%
 5  Excluded  Excluded
Sepsis 63.0%  47.9%
Mechanical ventilation  80.6%  73.9%
Illness severity score  APACHE II: 26.4  APACHE III: 102.4
Total SOFA score (respiratory, cardiovascular,   7.55  7.40
liver, coagulation)
Modalities of RRT  CVVHDF, SLEDD, or IHD  CVVHDF
RRT prior to randomization  64.3% (only patients who had undergone fewer   0% (patients with prior RRT excluded)
    than two sessions of IHD or SLEDD or less than 
    24 hours CRRT were included)
Commenced on CRRT  69.7%  100%
CRRT mode  Pre-dilution CVVHDF  Post-dilution CVVHDF
CRRT high-dose effl   uent target  35 mL/kg per hour  40 mL/kg per hour
CRRT low-dose effl   uent target  20 mL/kg per hour  25 mL/kg per hour
Time from ICU admission to fi  rst study RRT  6.7 days  2.1 days
Urea at study enrolment  23.8 mmol/L  24.2 mmol/L
Achieved dose of CRRT (high dose)  27.1 mL/kg per hourb  33.4 mL/kg per hour
Achieved dose of CRRT (low dose)  17.5 mL/kg per hourb  22 mL/kg per hour
Mean daily urea on CRRT (high dose)   11.7 mmol/L  12.7 mmol/L
Mean daily urea on CRRT (low dose)  16.8 mmol/L  15.9 mmol/L
Daily fl  uid balance on therapy  +130 mL  –20 mL
Survival at day 60  47.5%  Not reported
Survival at day 90  Not reported  55.3%
Percentage of survivors dependent on RRT   
  At day 28   45.2%  13.3%
  At day 60   24.6%  Not reported
  At day 90   Not reported  5.6%
aWhere baseline renal function was not available, patients are assumed to have normal baseline renal function. bDose was corrected for pre-dilution at median blood 
fl  ow and replacement rates. APACHE, Acute Physiology and Chronic Health Evaluation; CKD, chronic kidney disease; CRRT, continuous renal replacement therapy; 
CVVHDF, continuous veno-venous hemodiafi  ltration; ICU, intensive care unit; IHD, intermittent hemodialysis; RENAL, Randomized Evaluation of Normal versus 
Augmented Level; RRT, renal replacement therapy; SLEDD, slow extended-duration daily dialysis; SOFA, Sequential Organ Failure Assessment; VA/NIH ATN, Veterans 
Aff  airs/National Institutes of Health Acute Renal Failure Trial Network.
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determined criteria for the initiation of RRT in the 
RENAL study [8] were randomly assigned to post-dilution 
CVVHDF with an eﬄ   uent ﬂ  ow of 40 mL/kg per hour or 
25 mL/kg per hour. All patients received CRRT as their 
ﬁ  rst mode of RRT; only a small proportion of patients 
(approximately 7%) received IHD later in their ICU stay, 
and this proportion was similar to that of patients who 
remained dependent on dialysis at day 90. A small 
number of patients requiring an extended period of post-
ICU RRT accounted for the higher mean duration of RRT 
(11.5 ± 18.0 days and 13.0 ± 20.8 days in the two 
treatment groups) despite a duration of study treatment 
of only 5.9 ± 7.7 and 6.3 ± 8.37 days. Th   e RENAL study 
thus constitutes a more direct measure of the relationship 
between intensity of CRRT and survival.
Both studies failed to detect any reduction in mortality 
associated with a more intensive RRT. In addition, no 
signiﬁ  cant diﬀ  erences in mortality rates were observed 
between high-intensity and low-intensity treatment in 
pre-speciﬁ  ed subgroups in either study. Th  ese  subgroups 
included patients with sepsis and those requiring vaso-
pressors. Th  ese results now provide deﬁ  nitive evidence 
that an increase of CRRT dose beyond conventional 
eﬄ   uent ﬂ  ow rates of 25 mL/kg per hour is not beneﬁ  cial 
for unselected ICU patients with AKI. Importantly, both 
the ATN study and the RENAL study demonstrated that 
the prescribed dose is typically 10% to 15% less than the 
delivered dose in these patients, presumably because of 
treatment downtime. Th  is observation is important 
because downtime may be longer outside of the environ-
ment of a clinical trial and clinicians seeking to replicate 
these outcomes will need to account for this in their 
prescription. In contrast to the within-trial comparisons, 
important diﬀ   erences between overall survival and 
recovery of renal function in the ATN and RENAL 
studies can be highlighted (Table 2). Th  ese  diﬀ  erences do 
not detract from the consistent primary results within 
the trials and may be accounted for by diﬀ  erences in 
population and case mix. However, they also suggest that 
other aspects of RRT provision, such as timing of therapy 
[21] and prevalence of IHD, may impact outcomes and 
should be the subject of further study [3].
After the publication of the above pivotal trials, it was 
speculated that the relationship between CRRT dose and 
survival is at a plateau between 20 and 40 mL/kg per hour 
but that lower or much higher doses could be associated 
with worse outcomes (Figure 1) [22]. Certainly, there is 
now little incentive to use doses of greater than 25 mL/kg 
per hour in unselected ICU patients. It may be speculated 
that individual patients might beneﬁ   t from diﬀ  ering 
doses of CRRT; however, there was no suggestion that 
speciﬁ   c groups beneﬁ   ted in subgroup analysis of the 
ATN and RENAL trials, indicating that identiﬁ  cation of 
such patients may be diﬃ   cult. Similarly, diﬀ  erent target 
doses of CRRT may be suﬃ     cient at various stages of 
critical illness, but this question has not been examined 
in prospective random  ized controlled trials.
Th   e absence of improved survival with dose increment 
above 20 mL/kg per hour should not be taken as an 
indica  tion that assessment of dose is irrelevant, and lower 
intensities still will suﬃ   ce. It can be reasonably presumed 
that some relationship for increasing survival with 
intensity of therapy exists as one increases intensity from 
no therapy to a greater level of therapy, with a plateau 
response occurring at or before 20 to 25 mL/kg per hour. 
It seems unlikely that this plateau is occurring much 
before a dose of 20 mL/kg per hour. In the DO-RE-MI 
study [12], patients in the second tertile of dose (23.6 to 
30.9 mL/kg per hour) had the lowest mortality, with an 
adjusted odds ratio for death of 0.67, compared with 
doses of less than 23.6 mL/kg per hour, but this trend was 
far from statistically signiﬁ  cant (P = 0.196).
Historically, introduction of CRRT into the ICU led to 
improved survival when compared with previous use of 
thrice-weekly conventional IHD or acute peritoneal 
dialysis (PD) [23]. In this setting, use of CRRT led to 
improved azotemic control in comparison with the 
historical cohort, suggesting that increased survival may 
have been partly associated with delivery of a higher 
standardized dose of therapy. Similarly, a randomized 
control trial of CVVHF versus acute PD in patients with 
falciparum malaria or sepsis [24] demonstrated that 
CVVHF (mean prescribed dose of 19 mL/kg per hour) was 
associated with improved survival over continuous PD (2-
L exchanges with 30-minute dwell time) (mortality of 15% 
versus 47%; P = 0.005). While modality-related factors 
undoubtedly played a role in these results, the rate of 
decline in creatinine was twice as fast in those treated with 
CVVHF in comparison with those treated with PD, 
suggesting that the dose of small-molecular clear  ance 
delivered may have, in part, determined outcome.
By analogy, in the setting of end-stage renal disease, 
while doses of thrice-weekly IHD above an equilibrated 
Kt/V (eKt/V) of greater than 1.16 have not been asso  cia-
ted with improved outcomes [25], observational data 
have shown that an eKt/V of less than 1.05 is linearly 
associated with decreased survival in patients with end-
stage renal disease [26,27]. Th  rice-weekly IHD with an 
eKt/V of 1.05 provides azotemic control similar to that of 
approximately 11 mL/kg per hour of CRRT, according to 
the peak concentration method of dose comparison [28], 
and somewhat more if time-averaged urea concentration 
[29] is used as a comparator. It seems unlikely that the 
critically ill will have a lower requirement for RRT in 
comparison with stable HD patients. Th  ese considera-
tions, therefore, suggest that we should not tolerate doses 
of CRRT in critically ill patients near the inﬂ  exion point 
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population. Collectively, all of the observations provide 
strong circumstantial evidence that CRRT doses of less 
than 20 mL/kg per hour are likely to be harmful and 
should be avoided. Th   us, to guarantee outcomes similar 
to those seen in the ATN and RENAL studies and to have 
conﬁ   dence that an eﬀ   ective dose of CRRT has been 
delivered, clinicians should prescribe 20 to 30 mL/kg per 
hour on the basis of body weight at time of commence-
ment of CRRT and ensure that excessive periods oﬀ   of 
treatment are not compromising dose delivered. Notably, 
international surveys [11,12] have reported that, even 
now, a signiﬁ  cant minority of patients receive treatment 
intensities of less than 20 mL/kg per hour and may be 
suboptimally treated. If RRT doses are increased by 
adoption of these targets, clinicians should be aware that 
adjustments in drug (most importantly, antibiotic) dosing 
may be required to allow for increased clearances.
Special circumstances
A number of authors have hypothesized that subgroups 
of the critically ill, particularly those with sepsis or multi-
organ failure, might beneﬁ  t from a more intensive CRRT. 
It is thought that removal of circulating pro- and anti-
inﬂ  ammatory mediators might blunt systemic derange  ment 
of immune responses in severe critical illness [30,31]. In 
the ATN and RENAL trials, there was no beneﬁ  t from 
higher dose in any subgroup, including sepsis and 
vasopressor requirement. However, animal models [32-
34], which have suggested beneﬁ  cial eﬀ  ects of CRRT on 
the severity of systemic inﬂ  ammatory responses, employed 
very-high-dose therapy (greater than 50 mL/kg per hour) 
initiated very early in the course of illness (prior to overt 
renal dysfunction). Dose-response studies of conventional 
CRRT, such as the ATN and RENAL trials, were not 
intended to examine these pleiotropic eﬀ  ects of CRRT in 
critical illness. A detailed discussion of this topic is beyond 
the scope of this review; however, as such immune-
modulating eﬀ  ects are often cited as a rationale for dose 
adjustment of CRRT in severe sepsis, it is pertinent to 
brieﬂ  y discuss the current evidence base for such use of 
high-intensity CRRT in carefully selected patients.
Very-high-volume CRRT has been examined in un-
controlled clinical trials and case series with sugges  tion 
of beneﬁ   t [35-39]. As removal of middle-molecular-
weight mediators was desired, purely convective therapy 
(HF) was used in most of these studies. Very-high-
volume HF has been deﬁ  ned as a dose of greater than 
50 mL/kg per hour [40], although many studies have used 
higher doses. In practice, delivery of doses of CVVHF in 
excess of 50 mL/kg per hour is complex, presenting a 
number of clinical and technical challenges [40] that may 
account for the lack of high-quality clinical trial data to 
conﬁ  rm or refute a beneﬁ  t. An MC-RCT, the IVOIRE 
(High Volume in Intensive Care) study, examining the 
use of high-volume versus intermediate-dose CRRT (70 
versus 35 mL/kg per hour for 96 hours in patients with 
septic shock and moderate kidney injury) has recently 
stopped recruiting as interim analysis revealed lower-
than-expected mortality in all patients, rendering the 
planned study size (480 patients) insuﬃ     ciently powerful 
to prove an eﬀ   ect on survival [41]. Interest has thus 
focused on other methods of blood puriﬁ  cation  – 
including coupled plasma ﬁ  ltration with bioadsorption 
[42] or hemoﬁ   ltation using high-cutoﬀ    point (greater 
than 50 kDa) membranes [43,44] – that may be easier to 
clinically implement. As yet, the adjunctive uses of CRRT 
and related technologies for the treatment of severe 
sepsis and multi-organ failure remain experimental and 
are subject to ongoing trials. However, given the 
complexity of these treatments and the diverse patient 
population, direct proof of survival beneﬁ   t may be 
diﬃ     cult to obtain and surrogate endpoints such as 
vasopressor requirements and organ failure scoring may 
form the basis of practice recommendations in the future.
Conclusions
Th  e ATN and RENAL studies have now established an 
upper limit of intensity for CRRT. In addition, they found 
Figure 1. Possible relationship between delivered dose of 
continuous renal replacement therapy and survival, with results 
from the ATN and RENAL trials illustrated. ATN doses are corrected 
for pre-dilution. These studies indicate a plateau response at the dose 
ranges examined. To reproduce these results, clinicians will need to 
prescribe continuous renal replacement therapy doses above the 
lower target dose in the trial protocols (20 or 25 mL/kg per minute) 
as larger periods of fi  lter downtime can be expected outside a clinical 
trial environment. Below this best-practice region, survival is likely to 
be dose-dependent; however, the exact nature of this relationship 
has not been formally determined. Doses above the best-practice 
region are unlikely to be benefi  cial to unselected patients and could 
potentially be harmful. ATN, Veterans Aff  airs/National Institutes 
of Health Acute Renal Failure Trial Network; RENAL, Randomized 
Evaluation of Normal versus Augmented Level. Adapted from [18].
      







	





 			
	


	
	
	
	 


!	
	"
"#

$ $	
	
%
&

'

'





(

	'		
)""&	

*+
	
#,- ,$
Prowle et al. Critical Care 2011, 15:207 
http://ccforum.com/content/15/2/207
Page 6 of 8no evidence to suggest that any speciﬁ  c subgroups would 
beneﬁ   t from higher doses of RRT, refuting previous 
smaller studies [14]. Th  e  ﬁ  ndings of these studies, how-
ever, do not imply that the estimation of dose is unim-
portant. A dose-response relationship is likely at lower 
treatment intensities (that is, less than 20 mL/kg per 
hour), and a signiﬁ  cant minority of patients still receive 
treatment intensities less than this [11,12]. Given the 
likelihood of a dose-response relationship somewhere 
below 20 mL/kg per hour, delivery of doses lower than 
this should be avoided [22]. To ensure outcomes similar 
to those seen in the ATN and RENAL trials, clinicians 
should also prescribe CRRT on the basis of patient body 
weight to the established eﬄ   uent ﬂ  ow rate target of 20 to 
25 mL/kg of body weight per hour.
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